Visit Natera.com

Investor Relations

Set Up Alert

About Natera

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health.

 

Our cutting-edge cfDNA technology platform combines novel molecular biology techniques with bioinformatics software and AI, allowing detection down to a single molecule in a tube of blood. We’ve leveraged this platform to develop the most accurate non-invasive prenatal test on the market (Panorama™), the first tumor-specific assay for truly individualized cancer care (Signatera™), and best-in-class rejection assessment for kidney transplantation (Prospera™), among other transformative cfDNA tests.

 

Natera has performed more than 3 million cfDNA tests in its laboratories, more than any other, studied over 1.3 million patients and has been published in over 50 peer reviewed publications.

 
Learn More
 
Natera San Carlos

Stock Information

Change
Volume
52 Week High
52 Week Low

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Learn More

Recent News

October 18, 2021
Natera Expands Organ Health Business With Commercial Launch of the Prospera™ Lung Transplant Assessment Test
Results of VALID study presented at CHEST 2021 yield an AUC of 0.91 for Prospera Lung AUSTIN, Texas , Oct. 18, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA (cfDNA) testing, announced the launch and availability of its Prospera
More
October 11, 2021
Natera Announces New Publication Validating Signatera® Velocity Metric to Improve Cancer Management
Peer-reviewed study in stage III colorectal cancer demonstrates the prognostic value of ctDNA growth rate as measured by Signatera in over 1200 plasma samples AUSTIN, Texas , Oct. 11, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in transforming care through genetic and cell-free DNA
More
October 6, 2021
Natera Announces Completion of the Largest Prospective Validation Study of a Commercial Cell-Free DNA Test in Lung Transplantation
Results from the VALID study accepted for presentation of late breaking abstract at premier CHEST conference AUSTIN, Texas , Oct. 6, 2021 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in improving patient outcomes through genetic and cell-free DNA (cfDNA) testing, announced the completion
More
September 29, 2021
Court Rules in Natera's Favor Invalidating All of CareDx's Asserted Patents
AUSTIN, Texas , Sept. 29, 2021 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), is pleased that the Delaware Federal District Court ruled today that all three patents CareDx has asserted against Natera "are invalid as a matter of law under §101 for claiming patent-ineligible subject matter." 1 Natera
More
September 17, 2021
Natera Releases New Clinical Data at ESMO 2021 in Gastroesophageal Cancer and Uveal Melanoma
Data suggests that ctDNA dynamics may be a better surrogate of overall survival than radiographic imaging (RECIST criteria) AUSTIN, Texas , Sept. 17, 2021 /PRNewswire/ -- Natera, Inc.  (NASDAQ: NTRA), a leader in cell-free DNA testing, today announced new data being presented by the company and its
More
Read More

Upcoming Events

More events are coming soon.


Learn More

Past events

Read More

Recent Presentations

Learn More
The information provided in this area of the website is maintained by a third-party service. Natera is not responsible for the accuracy, currency or completeness of the information contained herein.

Data Provided by Refinitiv. Minimum 15 minutes delayed.